Evidence map›Paper›PMID 40905733›Full record

ReviewFEMS yeast research2025

Metabolic versatility of the Wickerhamiella/Starmerella yeast clade: from sugar utilization to lipid metabolism.

Meriam Vandeputte, Emma Diependaele, Inge Noëlle Adriënne Van Bogaert

Abstract readReview
In one paragraph

Review in FEMS yeast research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Meriam VandeputteCentre for Synthetic Biology, Department of Biotechnology, Ghent University, Ghent 9000, Belgium.ORCID 0000-0002-5703-7483
Emma DiependaeleCentre for Synthetic Biology, Department of Biotechnology, Ghent University, Ghent 9000, Belgium.ORCID 0009-0004-8235-5813
Inge Noëlle Adriënne Van BogaertCentre for Synthetic Biology, Department of Biotechnology, Ghent University, Ghent 9000, Belgium.ORCID 0000-0001-8144-6466

Funding

FWO 1SHB024N
6 · The paper itself

Abstract

The Wickerhamiella/Starmerella (W/S) yeast clade has recently gained attention as a "treasure trove" of metabolic diversity, characterized by unusual pathways shaped through complex evolutionary events. One of their most distinctive traits is their specialized sugar metabolism, which allows them to thrive in sugar-rich environments. While their role in sugar utilization is well established, emerging evidence suggests that some W/S species can also metabolize hydrophobic compounds, indicating a broader capacity for lipid-related processes. For instance, several W/S species produce sophorolipids (SLs)-a class of glycolipids with commercial applications as sustainable biosurfactants. This ability has sparked growing interest in their potential to synthesize a diverse range of lipids, including glycolipids and dicarboxylic acids. This mini-review explores the evolution and distinctive metabolic features of the W/S clade, focusing not only on its well-characterized sugar metabolism but also on its lesser-known lipid metabolism. Particular attention is given to SL production and the expansion and diversity of cytochrome P450 family 52 enzymes within this underexplored group, emphasizing their biotechnological potential in lipid biosynthesis and their promising applications in sustainable bioprocesses.

Indexed as

Carbohydrate MetabolismLipid MetabolismSaccharomycetalesSugarsGlycolipidsMetabolic Networks and PathwaysOleic AcidsGlycolipidsOleic AcidssophorolipidSugarsCYP52metabolic evolutionsophorolipidsugar metabolismWickerhamiella/Starmerella cladeyeast

Identifiers

PMID40905733
PMCPMC12461148

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.